Although several studies have attempted to investigate association between PON1 polymorphisms and cancer susceptibility, to the best of our knowledge, no study has focused on the relationship between PON1 polymorphisms and chemotherapeutic outcomes including the response rate, PFS, and OS. The gene discussed is PON1; the disease is cancer.